Arachidonoyl ethanolamide (AEA; Item No. 90050) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as D9-THC (Item No. 12068).{1134,2713} Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG; Item No. 62160).{2713} The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo. Here it acts with essentially the same potency as AEA.{11520} However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist with a Ki of about 200 nM.{9580} The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-P on the various LPA receptors have not been tested.
5 mg
CAS number
Cayman Chemical
Shipping & storage
Shipping condition
Dry Ice
Storage temperature